Germany – Medicines – Open House Biologics Discount Agreements 2026-03a - Eculizumab (excl. indications gMG and NMOSD)
Deutschland – Arzneimittel – Open-House-Biologika-Rabattverträge 2026-03a - Eculizumab (exkl. der Indikation gMG und NMOSD)
Germany · Hamburg
What the buyer is looking for
Ziel ist der Abschluss von Arzneimittelrabattverträgen nach § 130a Abs. 8 SGB V zu dem Wirkstoff Eculizumab (exkl. der Indikation gMG und NMOSD) im Rahmen eines Open-House-Verfahrens.
Description as published (DE).
Contract
BuyerTechniker Krankenkasse
TypeSupplies
Estimated valuevalue not published
Published25 February 2026
CategoryMedical equipment & pharma · CPV 33600000
Who has won here before
| Company | Awards | Period |
|---|---|---|
| Computacenter AG & Co. oHG | 76 | 2006–2026 |
| Siehe im Feld "Allgemeine Informationen" | 55 | 2023–2026 |
| Hexal AG · Holzkirchen | 43 | 2011–2026 |
| Aliud Pharma GmbH · Laichingen | 38 | 2011–2025 |
| Aristo Pharma GmbH · Berlin | 33 | 2012–2026 |
From 13.7M documented awards · regular winners know this buyer's requirements — that is your competition.
How often this buyer tenders this
201986
202036
202122
202229
202354
2024263
20251
2025550
2026275
Who knows the rhythm prepares instead of reacting.
376
days until the deadline — Tuesday 31 August at 00:00
How to bid
Read the full notice — Original + documents
Goes directly to this tender on TED — Tenders Electronic Daily. The full specification and all annexes are there.
Tenders like this, every morning at 7:30 in your inbox.
Start free →